Angelo Tzarevski

Advised Hitachi, Inc. on successfully obtaining merger clearance in South Africa and Namibia in respect of its global acquisition of the power grid business of Swiss-based ABB Ltd. valued at approximately USD 11 billion.

Advised GlaxoSmithKline in obtaining merger clearance in South Africa for its USD 12.7 billion acquisition of the global consumer healthcare business of Pfizer, Inc.

Advised Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), a multinational speciality pharmaceutical company, in successfully obtaining merger approval in South Africa and Namibia for the sale of its global subsidiary, iNova Pharmaceuticals, to a private equity consortium for USD 930 million.

Acting for a Japanese automotive component manufacturer in relation to ongoing investigations by the South African antitrust authorities involving allegations of collusion.

Acting for Unilever in relation to ongoing complaint proceedings by the South African antitrust authorities involving allegations of cartel conduct.

Advising a global media distribution, sports, events and talent management company in relation to leniency proceedings in South Africa.

Advised Fluidra S.A., a listed Spainish manufacturer of swimming pool equipment, in successfully obtaining merger clearance in South Africa for its merger involving Rhone Capital LLC valued at EUR 1 billion.

Advised Clariant AG in relation to the South African antitrust aspects of its global merger with Huntsman Corporation, valued at approximately USD 20 billion, which was subsequently abandoned.

Acted for a multinational vertically integrated steel making and mining company in successfully blocking the forced acquisition of its South African subsidiary.

Advised a French private equity fund in relation to COMESA merger control issues in a transaction involving the acquisition of businesses in Mauritius, Kenya and Malawi.